Business

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy.

articleOsr Holdings, Inc.January 22, 20264/company/osr-holdings-inc/news/woori-io-an-osr-company-highlights-fda-clarification-on-non-medical-wearables-as-a-catalyst-for-accelerated-commercial-launch
Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

About this update from Osr Holdings, Inc.

[{"type":"text","content":"BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conducive to Woori IO's commercialization strategy.","length":406,"tagName":"p"},{"type":"image","alt":"OSR Holdings logo (PRNewsfoto/OSR Holdings)","displaySize":"","headline":null,"caption":"OSR Holdings logo (PRNewsfoto/OSR Holdings)","className":"","disableSlideshowImg":false,"size":{"original":{"width":334,"height":277,"url":"https://media.zenfs.com/en/prnewswire.com/d1cf26310f8a0d3a1f4f003318d5e702"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cTh6l6BCVhUkYFTe3KonaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTUzMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d1cf26310f8a0d3a1f4f003318d5e702","width":334,"height":277}},"href":"https://mma.prnewswire.com/media/2393302/OSR_Holdings_logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The FDA has clarified that consumer wearable products providing non-medical, wellness-oriented health insights—when appropriately labeled and marketed—generally fall outside the scope of medical device pre-market review. Woori IO believes this regulatory clarity enables the Company to meaningfully accelerate time-to-market by first launching consumer-grade, lifestyle-management wearable solutions, while continuing its longer-term development roadmap toward medical-grade noninvasive continuous glucose monitoring (CGM) systems.","length":531,"tagName":"p"},{"type":"text","content":"Phased Commercial Strategy Aligned with Global Platform Partnerships","length":68,"tagName":"p"},{"type":"text","content":"Woori IO is pursuing a two-phase commercialization strategy designed to balance speed, regulatory discipline, and long-term clinical ambition:","length":142,"tagName":"p"},{"type":"text","content":"Phase 1: Consumer-Grade Wellness Wearables","length":42,"tagName":"p"},{"type":"text","content":"Products and software features intended to provide noninvasive, glucose-related insights for lifestyle, nutrition, and activity management. These offerings are positioned as general wellness tools and are not intended for diagnos...

More updates from Osr Holdings, Inc.

Woori IOOSRFDAOSR Holdingscommercializationmedical device